Patient case (clinical description): A 43-year-old woman, gravida 3 para 3, comes to the clinic complaining of recently painful menstrual cycles.  The patient's last menstrual period was 2 weeks ago. Urine β-hCG is negative. Menarche was at age 12, and menstrual periods occur every 28 days and lasts for 5 days.  She is sexually active with her husband and does not have pain with intercourse. BMI is 23 kg/m2 and Vital signs are normal.  On physical examination, the uterus is uniformly enlarged and tender. She is candidate for hysterectomy with the diagnosis of adenomyosis.

Patient's own account: I'm 43, and I paid a visit to my doctor because my last few periods were insanely painful. My last periods were 2 weeks ago. I already had three pregnancies that gave me the three lovely children. I did a urine test to check for potential pregnancy, and it came back negative. I started to have my periods at the age of 12, and I have been pretty regular with periods every 28 days for 5 days. I'm sexually active with my husband and I do not have any pain when we have sex. My BMI is 23 and my vitals were normal. The doctor performed a physical exam and found that my uterus was tender and enlarged. She proposed me a hysterectomy and diagnosed me with adenomyosis.

Clinical trial: Effect of Sex Hormone During the Menstrual Cycle on Capsaicin Evoked Cough Responses

Eligibility criteria:
Inclusion Criteria:

          1. Subjects must be aged between 18 to 35 years

          2. Have a diagnosis of atopic asthma (based on at least one positive skin prick test and
             methacholine PC20 ≤16 mg/ml)

          3. FEV1 ≥ 70% of predicted

          4. Demonstrate a cough response to capsaicin with a minimum of 3 coughs during the
             screening capsaicin challenge

        Exclusion Criteria:

          1. Subjects who are in a pollen season that affects their asthma

          2. Subjects who report allergies to capsaicin or bronchoconstrict at the end of the full
             dose capsaicin cough challenge and require short acting bronchodilator therapy (assess
             after visit 1)

          3. Subjects who do not display evidence of airway hyper-responsiveness (methacholine
             PC20>16mg/ml) (assess after visit 1)

          4. Symptoms of upper respiratory tract infection in the last 1 month which have not
             resolved.

          5. Lower respiratory tract infection or pneumonia in the last 6 weeks.

          6. Current smoker or ex-smoker with ≥10 pack year smoking history and abstinence of ≤6
             months

          7. Asthma exacerbation in the previous month requiring a start of inhaled or oral
             corticosteroids.

          8. Any asthma medication with the exception of infrequent (less than twice weekly)
             short-acting β2-agonist.

          9. Subjects who have changed asthma medication within the past 4 weeks prior to screening

         10. A previous asthma exacerbation requiring Intensive Care Unit admission.

         11. Significant other primary pulmonary disorders in particularly; pulmonary embolism,
             pulmonary hypertension, interstitial lung disease, lung cancer, cystic fibrosis,
             emphysema or bronchiectasis.

         12. Pregnancy or breast-feeding

         13. Use of ACE inhibitors

         14. Any centrally acting medication (opioids, gapapentin, pregabalin, amitriptyline) which
             in the view of the investigator could alter the sensitivity of the cough reflex

         15. History of psychiatric illness, drug or alcohol abuse which may interfere in the
             participation of the trial.

         16. History of current or previous anabolic steroid use in men.

         17. For the natural cycle group, the female patients must have regular (24 to 35 day)
             natural cycles and no oral contraceptive use for ≥6 months

         18. For female's taking the oral contraceptive pill they must be taking this ≥6 months

         19. Use of B-blockers

         20. Patients with clinically significant cardiovascular disease

         21. Patients with known allergy to any of the study medications or excipients

         22. Patients with a known potentially life threatening allergy (e.g. food allergy,
             stinging insect allergy), history of anaphylaxis, mastocytosis, angioedema
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 35 Years

Eligibility (NLI label): Contradiction